RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies

Exclusion Criteria

• •1. Subjects with concomitant genetic syndromes associated with bone marrow failure states.
• •2. Isolated extramedullary lesions
• •3. Subjects with some cardiac conditions will be excluded.
• •4. With uncontrolled active central nervous system leukemia (CNSL), cerebrospinal fluid grade CNS3.
• •5. History of traumatic brain injury, consciousness disturbance, epilepsy, cerebrovascular ischemia, and cerebrovascular hemorrhagic disease, which might compromise the ability of the subject to compliance with the obligations under the protocol.
• •6. History of malignancy other than non-melanoma skin cancer or carcinoma.
• •7. Primary immune deficiency.
• •8. Presence of uncontrolled infections.
• •9. Sujects with some anticancer therapy before CAR-T infusion will be excluded.
• •10. Active uncontrolled acute infections.
• •11. Known history of infection with human immunodeficiency virus (HIV); active or latent hepatitis B, hepatitis C and syphilis.
• •12. Subjects who are receiving systemic steroid therapy prior to screening.
• •13. Subjects with acute graft-versus-host disease (GvHD)
• •14. Having received live/attenuated vaccine within 4 weeks prior to screening.
• •15. History of allergy to any component of the cell therapy product.
• •16. Pregnant or breastfeeding women
• •17. Any other issue which, in the opinion of the investigator, would make the sujects ineligible for the study.